The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).
Eric Jay Small
No relevant relationships to disclose
Jack Youngren
No relevant relationships to disclose
Tomasz M. Beer
No relevant relationships to disclose
Charles J. Ryan
No relevant relationships to disclose
George Thomas
No relevant relationships to disclose
Nader Pourmand
No relevant relationships to disclose
Robert Evan Reiter
No relevant relationships to disclose
Joshi J. Alumkal
No relevant relationships to disclose
Joshua M. Stuart
No relevant relationships to disclose
Christopher P. Evans
No relevant relationships to disclose
Martin Edwin Gleave
No relevant relationships to disclose
Kim N. Chi
No relevant relationships to disclose
Alex Toschi
No relevant relationships to disclose
Adam Foye
No relevant relationships to disclose
Primo Lara
No relevant relationships to disclose
Owen Witte
No relevant relationships to disclose